Skip to content

Trial Summary

This study aims to screen patients with advanced cancer and unmet clinical needs for actionable biomarkers to be used to guide therapy.



ACTRN/NCT /ethics:


Scientific title:

The Cancer Molecular Screening and Therapeutics (MoST) Program – A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need.

Sponsor / Cooperative group:

The University of Sydney

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeEarly detection, diagnosis, prognosis
PhaseAll phases
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2016-09-09
Anticipated End Date2020-09-11

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorDr Chris Karapetis
Recruitment StatusRecruiting